Aaron, Elizabeth
Montgomery, Alicia
Ren, Xinguo
Guter, Stephen
Anderson, George
Carneiro, Ana M. D.
Jacob, Suma
Mosconi, Matthew
Pandey, Ghanshyam N.
Cook, Edwin
Veenstra-VanderWeele, Jeremy
Funding for this research was provided by:
National Institute of Child Health and Human Development (HD055751)
National Institute of Mental Health (MH094604)
National Institute of Mental Health (MH016434)
National Institute of Mental Health (MH106565)
Simons Foundation (Autism Research Initiative Simplex Project)
New York State Psychiatric Institute
Dr. Mortimer and Theresa Sackler Foundation
Article History
First Online: 29 March 2019
Compliance with ethical standards
:
: Jeremy Veenstra-VanderWeele has consulted or served on advisory boards for Roche, Novartis and SynapDx; has received research funding from Roche Pharmaceuticals, Novartis, SynapDx, Seaside Therapeutics, and Forest; and has received stipends for editorial work from Springer and Wiley. Edwin Cook has consulted with and received research funding from Seaside Therapeutics. Suma Jacob has received funding from Roche Pharmaceuticals. The remaining authors declare no competing interests.